“…Acute myocardial infarction (AMI) is a serious cardiovascular disease and a main cause of human death globally. − According to the existing methods, the detection of cardiac biomarkers is the most effective strategy for early AMI diagnosis. − Potential biomarkers with high feasibility are cardiac troponin I (cTnI), creatine kinase-MB isoenzymes (CK-MB), and heart-type fatty acid-binding protein (H-FABP), which are large molecular proteins in body fluids. − Despite cTnI being the “gold standard” for AMI diagnosis, its early-stage sensitivity is suboptimal. − Alternatively, H-FABP can be rapidly released into the blood when the myocardium is damaged, making it an ideal early-stage AMI marker with high sensitivity and specificity. ,,,− At present, various practicable methods are investigated to detect H-FABP, including lateral flow immunoassay, photoelectrochemical, fluorescence (FL) analysis, and electrochemical methods . However, these methods have some limitations, such as cumbersome procedures and a long operating time. − Consequently, there is a critical need for a convenient and accurate method to detect H-FABP in clinical settings.…”